Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research · 2006 · 2.6K citations · Full text

Medicine, Oncology, Pharmacology +16

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

Jing Yuan, Pramod P. Mehta, Min-Jean Yin et al. · Molecular Cancer Therapeutics · 2011 · 161 citations · Full text

Medicine, Oncology, Pharmacology +16

Differential Signaling Pathways Are Activated in the Epstein-Barr Virus-Associated Malignancies Nasopharyngeal Carcinoma and Hodgkin Lymphoma

Jennifer A. Morrison, Margaret L. Gulley, Pathmanathan Rajadurai et al. · Cancer Research · 2004 · 148 citations

Medicine, Cell Biology, Oncology +17

PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Amanda Herzog, Yansong Bian, Robert Vander Broek et al. · Clinical Cancer Research · 2013 · 87 citations

Medicine, Oncology, Pharmacology +16

GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death <i>In Vitro</i> and <i>In Vivo</i>

Jeffrey J. Wallin, Jane Guan, Wei Wei Prior et al. · Clinical Cancer Research · 2012 · 85 citations

Medicine, Oncology, Pharmacology +16